Skip to Main Content

Novartis AG

NVS Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Insiders
Institutions
Government
Ownership

$NVS is featured in our Shelley Moore Capito and Tom Carper strategies.

See All Strategies
Income
Balance Sheet
Cash Flow
NVS Income Statement
NVS Balance Sheet
NVS Cash Flow

Recent trades of NVS by members of U.S. Congress

Politician Type Traded
Sheldon Whitehouse Senate / D Sale (Partial) $1,001 - $15,000 Apr. 09, 2024
Sheldon Whitehouse Senate / D Purchase $15,001 - $50,000 Sep. 20, 2023
Daniel S. Goldman House / D Sale $50,001 - $100,000 Jul. 10, 2023
Thomas R. Carper Senate / D Purchase $1,001 - $15,000 Apr. 26, 2023
Daniel S. Goldman House / D Purchase $50,001 - $100,000 Mar. 31, 2023
Daniel S. Goldman House / D Sale $15,001 - $50,000 Feb. 27, 2023
Kevin Hern House / R Sale $1,001 - $15,000 Jan. 31, 2023
John H. Rutherford House / R Sale $1,001 - $15,000 Mar. 16, 2022
Donald S. Beyer, Jr. House / D Sale $1,001 - $15,000 Feb. 28, 2022
Donald S. Beyer, Jr. House / D Purchase $1,001 - $15,000 Jan. 27, 2022
Donald S. Beyer, Jr. House / D Sale $1,001 - $15,000 Dec. 22, 2021
Shelley Moore Capito Senate / R Sale (Full) $1,001 - $15,000 Dec. 15, 2021
Donald S. Beyer, Jr. House / D Sale $1,001 - $15,000 Sep. 17, 2021
Alan S. Lowenthal House / D Sale $1,001 - $15,000 Nov. 23, 2020
Alan S. Lowenthal House / D Sale $1,001 - $15,000 Nov. 23, 2020
Alan S. Lowenthal House / D Sale $15,001 - $50,000 Nov. 23, 2020
Donald S. Beyer, Jr. House / D Purchase $1,001 - $15,000 Nov. 17, 2020
Donald S. Beyer, Jr. House / D Sale $1,001 - $15,000 Oct. 05, 2020
Kevin Hern House / R Purchase $1,001 - $15,000 Jul. 27, 2020
Donald S. Beyer, Jr. House / D Sale $1,001 - $15,000 Jul. 14, 2020
Donald S. Beyer, Jr. House / D Sale $1,001 - $15,000 May. 07, 2020
Donald S. Beyer, Jr. House / D Sale $1,001 - $15,000 May. 04, 2020
Greg Gianforte House / R Purchase $1,001 - $15,000 Mar. 18, 2020
Mikie Sherrill House / D Sale $1,001 - $15,000 Feb. 20, 2020
Donald S. Beyer, Jr. House / D Purchase $1,001 - $15,000 Feb. 14, 2020
Donald S. Beyer, Jr. House / D Purchase $1,001 - $15,000 Jan. 27, 2020
Donald S. Beyer, Jr. House / D Purchase $1,001 - $15,000 Jan. 14, 2020
Donald S. Beyer, Jr. House / D Purchase $1,001 - $15,000 Dec. 26, 2019
Donald S. Beyer, Jr. House / D Purchase $1,001 - $15,000 Dec. 10, 2019
Donald S. Beyer, Jr. House / D Purchase $1,001 - $15,000 Nov. 26, 2019
Donald S. Beyer, Jr. House / D Purchase $1,001 - $15,000 Nov. 19, 2019
Mikie Sherrill House / D Sale $1,001 - $15,000 May. 28, 2019
John H. Rutherford House / R Purchase $1,001 - $15,000 Apr. 18, 2019
Jacky Rosen Senate / D Exchange $1,001 - $15,000 Apr. 08, 2019
Bill Cassidy Senate / R Sale (Partial) $1,001 - $15,000 Apr. 05, 2019
Nicholas V. Taylor House / R Sale $1,001 - $15,000 Mar. 25, 2019
Alan S. Lowenthal House / D Purchase $1,001 - $15,000 Feb. 15, 2019
Alan S. Lowenthal House / D Purchase $896.59 Feb. 15, 2019
Alan S. Lowenthal House / D Purchase $268.98 Feb. 15, 2019
Bill Cassidy Senate / R Purchase $1,001 - $15,000 Jan. 25, 2019
Bill Cassidy Senate / R Sale (Partial) $1,001 - $15,000 Dec. 07, 2018
Alan S. Lowenthal House / D Purchase $1,001 - $15,000 Nov. 30, 2018
Alan S. Lowenthal House / D Purchase $363.90 Nov. 30, 2018
Alan S. Lowenthal House / D Purchase $1,001 - $15,000 Nov. 30, 2018
Alan S. Lowenthal House / D Purchase $15,001 - $50,000 Nov. 29, 2018
Alan S. Lowenthal House / D Purchase $1,001 - $15,000 Nov. 29, 2018
Alan S. Lowenthal House / D Purchase $816.61 Nov. 29, 2018
Thomas MacArthur House / R Sale $1,001 - $15,000 May. 11, 2018
Thomas MacArthur House / R Purchase $1,001 - $15,000 Apr. 25, 2018
Shelley Moore Capito Senate / R Purchase $1,001 - $15,000 Apr. 24, 2018
NVS Stock Insider Trading Activity
Name
Type
Shares
Price
Shares Held
Date
Reported
NVS Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
NVS Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported

Recently reported changes by institutional investors

Quarterly net insider trading by NVS's directors and management

Quiver Logo

No recent Insider Trading for this ticker

Insider Trading Dashboard

Government lobbying spending instances

  • $40,000 Feb 04, 2003 Issue: Agriculture

Estimated quarterly lobbying spending

Quiver Logo

No Corporate Lobbying data for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Enhanced antigen presenting ability of rna car t cells by co-introduction of costimulatory molecules Dec. 10, 2024
  • Patent Title: Heteroaromatic nmda receptor modulators and uses thereof Dec. 10, 2024
  • Patent Title: Automatic drug delivery device Dec. 10, 2024
  • Patent Title: Selective octahydro-cyclopenta[c]pyrrole negative modulators of nr2b Dec. 10, 2024
  • Patent Title: Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof Dec. 03, 2024
  • Patent Title: Methods of treating dry eye disease using tnf alpha antagonists Nov. 19, 2024
  • Patent Title: N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[c]pyrrole negative allosteric modulators of nr2b Nov. 19, 2024
  • Patent Title: Nlrp3 inflammasome inhibitors Nov. 12, 2024
  • Patent Title: Process of manufacture of a compound for inhibiting the activity of shp2, as well as products resulting from acid addition Nov. 12, 2024
  • Patent Title: Compounds and compositions for treating conditions associated with nlrp activity Nov. 05, 2024
  • Patent Title: Hydroquinazoline derivatives for the treatment of a disease or disorder Oct. 29, 2024
  • Patent Title: 2-azaspiro[3.4]octane derivatives as m4 agonists Oct. 22, 2024
  • Patent Title: 3-(5-oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof Oct. 01, 2024
  • Patent Title: Rapamycin derivatives Sep. 17, 2024
  • Patent Title: Combination therapy Sep. 17, 2024
  • Patent Title: Crystalline forms of a tlr7/tlr8 inhibitor Sep. 10, 2024
  • Patent Title: Naphthyridinone derivatives for the treatment of a disease or disorder Sep. 10, 2024
  • Patent Title: Compounds and compositions for treating conditions associated with nlrp activity Sep. 10, 2024
  • Patent Title: Biaryl derivatives as yap/taz-tead protein-protein interaction inhibitors Sep. 10, 2024
  • Patent Title: Antiviral 1,3-di-oxo-indene compounds Sep. 10, 2024
  • Patent Title: Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders Sep. 03, 2024
  • Patent Title: Polyomavirus neutralizing antibodies Sep. 03, 2024
  • Patent Title: 10-(di(phenyl)methyl)-4-hydroxy-8,9,9a,10-tetrahydro-7h-pyrrolo[1′,2′:4,5]pyrazino[1,2-b]pyridazine-3,5-dione derivatives and related compounds as inhibitors of the orthomyxovirus replication for treating influenza Aug. 27, 2024
  • Patent Title: Immunosuppressant formulations Aug. 27, 2024
  • Patent Title: Anti-cd40 antibodies for use in treatment of sjögren's syndrome Aug. 20, 2024
  • Patent Title: Ribociclib tablet Aug. 20, 2024
  • Patent Title: Anti-baffr antibody formulations and methods of use thereof Aug. 06, 2024
  • Patent Title: Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor Aug. 06, 2024
  • Patent Title: Stable protein solution formulation containing high concentration of an anti-vegf antibody Jul. 30, 2024
  • Patent Title: Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof Jul. 30, 2024
  • Patent Title: Syringe Jul. 30, 2024
  • Patent Title: Medical container with nfc antenna Jul. 23, 2024
  • Patent Title: Compositions and methods for immunooncology Jul. 16, 2024
  • Patent Title: Variant cd58 domains and uses thereof Jul. 16, 2024
  • Patent Title: Combination therapy Jul. 16, 2024
  • Patent Title: Compounds and compositions for the treatment of cryptosporidiosis Jun. 25, 2024
  • Patent Title: Pulmonary hypertension biomarker Jun. 18, 2024
  • Patent Title: Factor xi antibodies and methods of use Jun. 18, 2024
  • Patent Title: N-substituted tetrahydrothienopyridine derivatives and uses thereof Jun. 18, 2024
  • Patent Title: Therapeutic combinations comprising a c-raf inhibitor Jun. 18, 2024
  • Patent Title: Antibody-il2 engrafted proteins and methods of use in the treatment of cancer Jun. 11, 2024
  • Patent Title: Compositions and methods for selective protein degradation Jun. 04, 2024
  • Patent Title: Human mesothelin chimeric antigen receptors and uses thereof Jun. 04, 2024
  • Patent Title: Anti-cd48 antibodies, antibody drug conjugates, and uses thereof Jun. 04, 2024
  • Patent Title: Crystalline forms of potassium channel modulators May. 28, 2024
  • Patent Title: Crystalline forms of a lta4h inhibitor May. 28, 2024
  • Patent Title: Method of manufacturing bispecific antibodies, bispecific antibodies and therapeutic use of such antibodies May. 21, 2024
  • Patent Title: Cd19 and cd22 chimeric antigen receptors and uses thereof May. 07, 2024
  • Patent Title: Tricyclic akr1c3 dependent kars inhibitors Apr. 30, 2024
  • Patent Title: Methods of treating hiv-haart induced partial lipodystrophy with fgf21 protein variant fc fusion proteins Apr. 23, 2024
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
Government Contracts

Estimated quarterly amount awarded from public contracts

Quiver Logo

No recent Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of NVS in WallStreetBets Daily Discussion

NVS News

Recent insights relating to NVS

CNBC Recommendations

Recent picks made for NVS stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in NVS

NVS Top Shareholders
Shareholder
Shares Held
NVS Options Owners
Shareholder
Security
Underlying Shares

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

NVS Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view NVS Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
Back To Top